Rating Rationale
December 31, 2021 | Mumbai
Olon Active Pharmaceutical Ingredients India Private Limited
Rating upgraded to 'CCR BBB+ / Stable'
 
Rating Action
Corporate Credit RatingCCR BBB+/Stable (Upgraded from 'CCR BBB/Stable')
1 crore = 10 million
Refer to Annexure for Details of Instruments & Bank Facilities

Detailed Rationale

CRISIL Ratings has upgraded its corporate credit rating to 'CCR BBB+/Stable' from 'CCR BBB/Stable' on Olon Active Pharmaceutical Ingredients India Private Limited (OAPIIPL).

 

Upgrade reflects enhanced business risk profile of the company on back sustenance of healthy operating margin resulting in higher cash accruals and thus better financial risk profile. Company’s operating margin continues to remain healthy at around 26.3% for fiscal 2021 which resulted in net cash accruals to remain healthy at Rs 48 crore and interest coverage ratio of above 13 times. Further, in absence of any debt funded capex plans, and zero reliance on external debt, financial risk profile should continue to remain healthy over the medium term.

 

The rating continues to reflect OAPIIPLs parents (Olon SPA) established presence in the pharmaceutical industry coupled with healthy operating efficiencies and moderate financial risk profile. These rating strengths are partially offset by working capital intensive nature of operations and moderate scale of operations with concentration in revenue profile.

Analytical Approach

CRISIL Ratings has treated unsecured loan from parent in from of external commercial borrowings (ECB) as debt as it as fixed repayment schedule. 

Key Rating Drivers & Detailed Description

Strengths:

* Established presence in the industry and healthy operational efficiencies: Extensive industry experience of the parent in the industry and experienced professional setup has helped the company in maintaining its operating performance with steady revenue of around Rs 237-246 crore during fiscal 2020 and 2021 at healthy operating margin of above 26%. Further, Company caters to customers such as Sandoz, Lupin among others. While it’s major contract is expected to end in March 2022, addition of new product to support sales. Major products include Active Pharmaceutical Ingredients (API) for treatment of tuberculosis which see steady demand from international bodies like World Health Organisation. Above parameters has resulted in return on capital employed to remain healthy at above 22%.

 

* Moderate financial risk profile: The total outside liabilities to adjusted networth ratio improved to 1.47 times as on March 31, 2021 from 2.6 times a year earlier. Further company has healthy networth base of Rs 106 crore as on March 31, 2021. Company has no external debt apart from the ECB from the parent. Debt protection metrics are comfortable with interest coverage ratio at 13.92 times in fiscal 2021. Financial risk profile is expected to continue to remain comfortable in absence of debt funded capex and inorganic acquisition if any to be funded by the parent.

 

Weaknesses:

* Working capital-intensive operations:  Gross current assets (net of liquid assets) were high at above 250 days, driven by debtors and inventory of 99 days and 182 days, respectively, as on March 31, 2021. Company currently has to maintain high inventory on account of offtake contract with Sandoz as well as variety of products in the portfolio. Improvement in inventory levels to remain sensitivity.

 

* Moderate scale of operations with concentration in revenue profile: Company’s scale of operations continues to remain moderate with revenue at Rs 246 crore in fiscal 2021. Further, currently company generates over 30% of the revenue from Rifamycin and related products and around 30% from the single contract. This risk is partly mitigated by expectation of new API addition over the medium term by the parent and other customers.      

Liquidity: Adequate

Company has adequate liquidity driven by expected cash accruals of around Rs 45-55 crore in fiscal 2022 and 2023 respectively against repayment obligation of external commercial borrowing from the parent of approx. Rs 13-14 crore each. It also has total unencumbered cash and cash equivalent of Rs 36 crore as on March 31, 2021. Current ratio was moderate at 4.3 times as on March 31, 2021. Company has capex plans of around Rs 5-10 crore per annum over the medium term to be funded from the internal accruals.

Outlook: Stable

CRISIL Ratings believes that company's business risk profile is expected to be benefited established presence, healthy clientele and technical & marketing support from its parent.

Rating Sensitivity factors

Upward factors:

  • Sustained and significant improvement in scale of operations above Rs 400 crores while and sustaining operating margin above 22%, leading to much higher accruals.
  • Improvement in working capital cycle and financial risk profile

 

Downward factors:

  • Significant decline in revenue and/ or dip in operating margin below 18% weakening net cash accruals much below current expectations
  • Stretch in working capital cycle, large debt-funded capex or large dividend payout weakening the financial risk profile or liquidity

About the Company

OAPIIPL was established in September 18, 2018 as a wholly owned subsidiary of foreign company (Olon SPA). Olon SPA is Italy based company, engaged in manufacturing of APIs through synthesis and biological process for generic market and CDMO (Contract development and manufacturing organization). OAPIIPL under slump sale purchased manufacturing plant from Sandoz located at Mahad, Maharashtra. Company is engaged in manufacturing of Active Pharmaceutical Ingredients and its intermediates.

Key Financial Indicators

Particulars Unit 2021 2020
Revenue Rs crore 246 237
Profit after tax (PAT) Rs crore 35 37
PAT margin % 14.4 15.8
Adjusted debt/adjusted networth Times 1 1.09
Interest coverage Times 13.92 12.94

 

Any other information: Not applicable

Note on complexity levels of the rated instrument:
CRISIL Ratings' complexity levels are assigned to various types of financial instruments. The CRISIL Ratings' complexity levels are available on www.crisil.com/complexity-levels. Users are advised to refer to the CRISIL Ratings' complexity levels for instruments that they consider for investment. Users may also call the Customer Service Helpdesk with queries on specific instruments.

Annexure - Details of Instrument(s)

ISIN

Name of instrument

Date of
allotment

Coupon
rate (%)

Maturity date

Issue size
(Rs crore)

Complexity Levels

Rating assigned
with outlook

NA

NA

NA

NA

NA

NA

NA

NA

 

Annexure - Rating History for last 3 Years
  Current 2021 (History) 2020  2019  2018  Start of 2018
Instrument Type Outstanding Amount Rating Date Rating Date Rating Date Rating Date Rating Rating
Corporate Credit Rating LT 0.0 CCR BBB+/Stable   -- 31-12-20 CCR BBB/Stable   --   -- --
All amounts are in Rs.Cr.
Criteria Details
Links to related criteria
CRISILs Approach to Financial Ratios
Rating criteria for manufaturing and service sector companies
The Rating Process
Understanding CRISILs Ratings and Rating Scales
Rating Criteria for the Pharmaceutical Industry

Media Relations
Analytical Contacts
Customer Service Helpdesk

Pankaj Rawat
Media Relations
CRISIL Limited
B: +91 22 3342 3000
pankaj.rawat@crisil.com

 


Naireen Ahmed
Media Relations
CRISIL Limited
D: +91 22 3342 1818
B: +91 22 3342 3000
naireen.ahmed@crisil.com


Rahul Subrato Kumar Guha
Director
CRISIL Ratings Limited
D:+91 22 4097 8320
rahul.guha@crisil.com


Jumana Badshah
Associate Director
CRISIL Ratings Limited
D:+91 22 3342 8324
Jumana.Badshah@crisil.com


Rushabh Pramod Borkar
Manager
CRISIL Ratings Limited
D:+91 22 33423390
Rushabh.Borkar@crisil.com
Timings: 10.00 am to 7.00 pm
Toll free Number:1800 267 1301

For a copy of Rationales / Rating Reports:
CRISILratingdesk@crisil.com
 
For Analytical queries:
ratingsinvestordesk@crisil.com


 

Note for Media:
This rating rationale is transmitted to you for the sole purpose of dissemination through your newspaper/magazine/agency. The rating rationale may be used by you in full or in part without changing the meaning or context thereof but with due credit to CRISIL Ratings. However, CRISIL Ratings alone has the sole right of distribution (whether directly or indirectly) of its rationales for consideration or otherwise through any media including websites and portals.


About CRISIL Ratings Limited (A subsidiary of CRISIL Limited)

CRISIL Ratings pioneered the concept of credit rating in India in 1987. With a tradition of independence, analytical rigour and innovation, we set the standards in the credit rating business. We rate the entire range of debt instruments, such as bank loans, certificates of deposit, commercial paper, non-convertible/convertible/partially convertible bonds and debentures, perpetual bonds, bank hybrid capital instruments, asset-backed and mortgage-backed securities, partial guarantees and other structured debt instruments. We have rated over 33,000 large and mid-scale corporates and financial institutions. We have also instituted several innovations in India in the rating business, including ratings for municipal bonds, partially guaranteed instruments and infrastructure investment trusts (InvITs).
 
CRISIL Ratings Limited ('CRISIL Ratings') is a wholly-owned subsidiary of CRISIL Limited ('CRISIL'). CRISIL Ratings Limited is registered in India as a credit rating agency with the Securities and Exchange Board of India ("SEBI").
 
For more information, visit www.crisilratings.com 

 



About CRISIL Limited

CRISIL is a global analytical company providing ratings, research, and risk and policy advisory services. We are India's leading ratings agency. We are also the foremost provider of high-end research to the world's largest banks and leading corporations.

CRISIL is majority owned by S&P Global Inc, a leading provider of transparent and independent ratings, benchmarks, analytics and data to the capital and commodity markets worldwide.


For more information, visit www.crisil.com

Connect with us: TWITTER | LINKEDIN | YOUTUBE | FACEBOOK


CRISIL PRIVACY NOTICE
 
CRISIL respects your privacy. We may use your contact information, such as your name, address and email id to fulfil your request and service your account and to provide you with additional information from CRISIL. For further information on CRISIL’s privacy policy please visit www.crisil.com.



DISCLAIMER

This disclaimer is part of and applies to each credit rating report and/or credit rating rationale (‘report’) that is provided by CRISIL Ratings Limited (‘CRISIL Ratings’). To avoid doubt, the term ‘report’ includes the information, ratings and other content forming part of the report. The report is intended for the jurisdiction of India only. This report does not constitute an offer of services. Without limiting the generality of the foregoing, nothing in the report is to be construed as CRISIL Ratings providing or intending to provide any services in jurisdictions where CRISIL Ratings does not have the necessary licenses and/or registration to carry out its business activities referred to above. Access or use of this report does not create a client relationship between CRISIL Ratings and the user.

We are not aware that any user intends to rely on the report or of the manner in which a user intends to use the report. In preparing our report we have not taken into consideration the objectives or particular needs of any particular user. It is made abundantly clear that the report is not intended to and does not constitute an investment advice. The report is not an offer to sell or an offer to purchase or subscribe for any investment in any securities, instruments, facilities or solicitation of any kind to enter into any deal or transaction with the entity to which the report pertains. The report should not be the sole or primary basis for any investment decision within the meaning of any law or regulation (including the laws and regulations applicable in the US).

Ratings from CRISIL Ratings are statements of opinion as of the date they are expressed and not statements of fact or recommendations to purchase, hold or sell any securities/instruments or to make any investment decisions. Any opinions expressed here are in good faith, are subject to change without notice, and are only current as of the stated date of their issue. CRISIL Ratings assumes no obligation to update its opinions following publication in any form or format although CRISIL Ratings may disseminate its opinions and analysis. The rating contained in the report is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment or other business decisions. The recipients of the report should rely on their own judgment and take their own professional advice before acting on the report in any way. CRISIL Ratings or its associates may have other commercial transactions with the entity to which the report pertains.

Neither CRISIL Ratings nor its affiliates, third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively, ‘CRISIL Ratings Parties’) guarantee the accuracy, completeness or adequacy of the report, and no CRISIL Ratings Party shall have any liability for any errors, omissions or interruptions therein, regardless of the cause, or for the results obtained from the use of any part of the report. EACH CRISIL RATINGS PARTY DISCLAIMS ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING BUT NOT LIMITED TO ANY WARRANTIES OF MERCHANTABILITY, SUITABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE. In no event shall any CRISIL Ratings Party be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees or losses (including, without limitation, lost income or lost profits and opportunity costs) in connection with any use of any part of the report even if advised of the possibility of such damages.

CRISIL Ratings may receive compensation for its ratings and certain credit-related analyses, normally from issuers or underwriters of the instruments, facilities, securities or from obligors. Public ratings and analysis by CRISIL Ratings, as are required to be disclosed under the regulations of the Securities and Exchange Board of India (and other applicable regulations, if any), are made available on its website, www.crisilratings.com (free of charge). Reports with more detail and additional information may be available for subscription at a fee – more details about ratings by CRISIL Ratings are available here: www.crisilratings.com.

CRISIL Ratings and its affiliates do not act as a fiduciary. While CRISIL Ratings has obtained information from sources it believes to be reliable, CRISIL Ratings does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives and/or relies on in its reports. CRISIL Ratings has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process. CRISIL Ratings has in place a ratings code of conduct and policies for managing conflict of interest. For details please refer to:
https://www.crisil.com/en/home/our-businesses/ratings/regulatory-disclosures/highlighted-policies.html.

Rating criteria by CRISIL Ratings are generally available without charge to the public on the CRISIL Ratings public website, www.crisilratings.com. For latest rating information on any instrument of any company rated by CRISIL Ratings, you may contact the CRISIL Ratings desk at crisilratingdesk@crisil.com, or at (0091) 1800 267 1301.

This report should not be reproduced or redistributed to any other person or in any form without prior written consent from CRISIL Ratings.

All rights reserved @ CRISIL Ratings Limited. CRISIL Ratings is a wholly owned subsidiary of CRISIL Limited.

 

 

CRISIL Ratings uses the prefix ‘PP-MLD’ for the ratings of principal-protected market-linked debentures (PPMLD) with effect from November 1, 2011, to comply with the SEBI circular, "Guidelines for Issue and Listing of Structured Products/Market Linked Debentures". The revision in rating symbols for PPMLDs should not be construed as a change in the rating of the subject instrument. For details on CRISIL Ratings' use of 'PP-MLD' please refer to the notes to Rating scale for Debt Instruments and Structured Finance Instruments at the following link: https://www.crisil.com/en/home/our-businesses/ratings/credit-ratings-scale.html